Searched for
ERIS LIFESCIENCES EARNINGS
Crorepati investors splurge $1 billion to buy these 10 stocks. Should you follow the smart money?Wealthy investors are making significant moves, pouring over $1 billion into ten select stocks. This concentrated buying occurs even as the...- Gainers & Losers: Nestle, Groww and Ola among 7 big movers on TuesdaySeven major stocks—including Nestle, Groww, Lemon Tree Hotels and Ola—logged sharp moves on Tuesday as markets rallied for a third straight...
- Adani Ports, ICICI Bank, Titan among top picks as PL Capital eyes 12-month Nifty target of 27,609Prabhudas Lilladher forecasts Nifty 50 at 27,609 over 12 months, citing India’s consumption revival, tax cuts, and easier credit. Top stock...
- Eris Lifesciences reports 41% year-on-year rise in net profit in Q1Eris Lifesciences reported a robust 41% YoY increase in net profit, reaching Rs 125 crore for the first quarter, driven by strong performan...
- Saurabh Mukherjea picks Berger Paints, 2 other stocks for mid and smallcap portfoliosAfter robust growth in FY24, corporate earnings momentum has slowed in the last two quarters, with BSE500’s weighted average PAT growth dro...
- Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25Eris acquired Biocon Biologics' domestic branded formulation business for Rs 1,242 crore in Q4FY24 and dermatology and nephrology units in ...
- Eris Lifesciences Q4 Results: Net profit jumps over 29% to Rs 80 croreThe Ahmedabad-based drug maker reported a net profit of Rs 61.5 crore during the corresponding quarter of the previous year. Revenue of Q4F...
- Buy Eris Lifesciences, target price Rs 710: Motilal Oswal Financial ServicesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 7871.82 Crore) operating in Pharmaceutica...
- Stocks in news: IndusInd Bank, ITC, ICICI Pru Life, Rail Vikas, Delta Corp, Glenmark PharmaIndusInd Bank will report its earnings for the December quarter on Wednesday. The bank is expected to report strong growth in income on the...
- Eris Lifesciences Q4 Results: Net profit rises 17% to Rs 80 croreOn the outlook, Eris Lifesciences said it has an exciting pipeline of 'patent expiration' opportunities coming up in the cardiometabolic se...
- Eris Lifesciences Q3 Results: Profit rises to Rs 101 croreRevenue stood at Rs 332 crore in the third quarter of the current fiscal as compared to Rs 310 crore in the year-ago period, Eris Lifescien...
- Market Movers: Resurgent Covid brings tailwinds for healthcare stocksShares of healthcare stocks – pharma companies and diagnostic companies – jumped in trade today as the government got into battle mode to s...
- Eris Lifesciences Q3 results: Net profit up 42% at Rs 90 croreConsolidated total revenue from operations of the company stood at Rs 310.42 crore for the quarter under consideration. It was Rs 266.39 cr...
- Stocks in the news: SBI, Happiest Minds, Adani Enterprises and Kotak Mahindra BankKotak Mahindra Bank announced that it has reduced its interest rates on home loans by a further 15 basis points (bps) to 6.75 per cent.
- These midcaps could return up to 35% in a yearThe stock, with a return on equity of 15% and return on capital employed of 19%, can give 22% returns in the next one year, according to Bl...
- Eris Lifesciences Q4 results: Net profit up 4% to Rs 56 croreThe company posted a net profit of Rs 53.88 crore for January-March period of 2018-19.
- Board Meetings Today: Britannia Industries, Motherson Sumi Systems, InterGlobe Aviation and Eris LifesciencesIt makes sense to have a look atthe corporate agendas for the day’s as announced to the stock exchanges
- Analyst Calls: Ambuja Cements,SpiceJet, ICICI Bank, Essel PropackIIFL has maintained reduce rating on Ambuja Cements with a target price of Rs 198.
- For HNIs to make profit, CDSL has to list at 65-75% premiumThe grey market premium indicates a high possibility of HNIs losing money on listing day.
- Should you invest in Eris Lifesciences?Despite being expensive, the issue holds a compelling investment proposition.
Load More
